Biotech

All Articles

Transgene's popular cancer vaccine fails midphase exam

.Transgene's restorative vaccine prospect TG4001 has actually flunked a phase 2 solid lump trial. Ho...

Upstream swells IPO to $255M as it provides alongside CAMP4

.Upstream Biography has puffy its IPO to $255 million as the company signs up with CAMP4 Therapies t...

Sanofi fails MS research study, giving yet another impact to Denali treaty

.Sanofi has actually stopped a stage 2 hardship of Denali Therapeutics-partnered oditrasertib in a n...

Turnstone lays off 60%, shakes up C-suite to extend cash money

.Turnstone Biologics is actually reducing its own head count by 60% and also shaking up its C-suite ...

Gilead gives up on $15M MASH bet after mulling preclinical records

.In a year that has seen an approval and also a raft of readouts for metabolic dysfunction-associate...

Texas biotech axes cancer cells deal, pins wishes on obesity

.Alaunos Therapeutics is axing a contract along with Precigen, quiting licensing liberties to a tail...

Capricor shares a lot more data for DMD therapy after triggering BLA

.Capricor Therapies is actually taking a success tour for their period 2 Duchenne muscle dystrophy (...

FDA places Kezar lupus trial in hold observing 4 individual fatalities

.The FDA has actually positioned Kezar Life Sciences' lupus test on grip after the biotech flagged f...

Phase 3 Scholar Rock test attacks SMA objective, sending out stockpile 200%

.A stage 3 trial of Scholar Rock's spinal muscular atrophy (SMA) applicant has actually hit its key ...

CAMP 4 is most current to eye IPO, while Upstream define $182M strategy

.RNA biotech CAMP4 Therapeutics has marked out think about a $67 million IPO, with inflammation-focu...